Rani Therapeutics to Participate in May Investor Conferences
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its price target raised by analysts at BTIG Research from $7.00 to $14.00. They now have a "buy" rating on the stock.
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024 [Yahoo! Finance]
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its price target raised by analysts at HC Wainwright from $12.00 to $13.00. They now have a "buy" rating on the stock.